Overview

• Healthcare professionals and researchers involved in MS clinical care or research.
• Neurologists.
• Clinical researchers.
• Residents with interest in Neurology.

• Pre-congress on December 3, 2026.
• Plenary sessions covering all major topics in MS.
• Full-day parallel session in collaboration with the IOMSNMSC aimed at MENA region nurses.
• European Charcot Foundation Symposium.

• MS Diagnosis.
• Biomarkers in MS.
• MS Treatment.
• Update on Progressive MS.
• Oral Presentations.
• Updates in MS.
• The Role of Patient Reported Outcomes.
• NMOSD and MOGAD.
• Hot Topics in MS.

Pre-congress activities include MENACTRIMS pre-congress activities, neuroimaging and neuroradiology parallel courses, along with educational foundation and industry-driven pre-congress sessions taking place in parallel.

Pre-congress registrations have a separate form.

• Learn about the latest advancements in Multiple Sclerosis (MS) research, including innovative therapies and new treatment approaches.
• Discover the role of biomarkers and precision medicine in personalizing MS treatment strategies.
• Understand the impact of genetics and environmental factors in MS pathogenesis and risk assessment.
• Explore cutting-edge disease-modifying therapies (DMTs) and their role in slowing disease progression.
• Gain insights into advanced imaging techniques, including high-resolution MRI, for better MS diagnosis and monitoring.
• Learn about the latest guidelines and updates in MS management, including best practices for relapse treatment and symptom control.
• Explore advancements in neurorehabilitation, lifestyle interventions, and mental health management for MS patients.
• Stay updated on novel treatment targets and immunotherapy advancements in MS.
• Discuss challenges in MS patient care, disability management, and healthcare policies to enhance quality of life.

MENACTRIMS is granted CME Category 1 by Dubai Health.